Amble Health, a direct-pay telehealth platform focused on metabolic care, has launched the Amble Cares Program, a national initiative that reduces the cost of weight-loss treatments—including GLP-1 prescriptions if eligible—by up to 50% for low-income Americans. The program is designed for individuals and families with limited disposable income, prioritizing parents and guardians. Eligibility is determined by an independent third-party verification partner based on verified financial need, not by Amble Health itself.
How it works
The program operates on a direct-pay model, meaning it does not accept insurance, Medicare, Medicaid, or HSA/FSA funds. Patients pay out of pocket at the reduced rate. Once a patient’s financial eligibility is verified through a secure third-party portal, they are connected directly to a licensed clinician for a consultation. The company states the process is designed to be immediate, with no drawn-out timelines or unnecessary steps.
Eligibility and pricing
Amble Health says the program is “built for access, not exclusivity.” The discount is not a temporary subsidy or limited pilot—it is a structural pricing change. Specific discount levels are determined by the third-party verifier based on the patient’s financial situation. The program explicitly targets those who have been priced out of GLP-1 therapy, which a recent KFF Health Tracking Poll found roughly 1 in 8 U.S. adults have taken.
Tradeoffs
The main tradeoff is that patients cannot combine the Amble Cares discount with any insurance coverage, including Medicare, Medicaid, or commercial plans. They also cannot submit claims for products purchased through Amble to any insurer or FSA/HSA account. This keeps administrative costs low and prices predictable, but it means patients must forgo any potential insurance reimbursement. The program is also limited to weight-loss program treatments that may include a GLP-1 prescription if eligible—it does not cover other metabolic conditions or general primary care.
When to use it
The Amble Cares Program is most useful for uninsured or underinsured individuals who have been unable to afford GLP-1 medications through traditional channels. It is also relevant for those whose insurance plans do not cover weight-loss treatments or impose high copays. The direct-pay model removes the delays and denials common with insurance-based care, making it a faster path to treatment for those who qualify.
Bottom line
Amble Health’s Cares Program is a targeted financial assistance initiative that addresses the affordability gap in GLP-1 access for low-income Americans. By cutting costs up to 50% and eliminating insurance bureaucracy, it offers a practical, if limited, alternative for patients who have been excluded from the current system. The program is live now; interested patients can apply through the Amble Health Eligibility Portal.